Phase 2 Clinical Trial of Attenuated<i>Salmonella enterica</i>Serovar Typhi Oral Live Vector Vaccine CVD 908-<i>htrA</i>in U.S. Volunteers
Carol O. Tacket(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore), Karen L. Kotloff(University of Maryland, Baltimore), Robert Edelman(University of Maryland, Baltimore), Judith G Perry(Park University), Steven S. Wasserman(University of Maryland, Baltimore), David Brown, Philip Bedford(e-Therapeutics (United Kingdom)), Genevieve A. Losonsky(University of Maryland, Baltimore), James P. Nataro(University of Maryland, Baltimore), Stephen Chatfield, Marcelo B. Sztein(University of Maryland, Baltimore), Gordon Dougan(University of Cambridge), Timothy Wyant(University of Maryland, Baltimore)
Cited by 181
Related Papers
Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet Infectious Diseases|2017|1.4k
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18
|Nature|2001|1.3k
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Typhoid Fever
|New England Journal of Medicine|2002|1.1k